Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (CELG) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Celgene, and see what CAPS investors are saying about the stock right now.
Celgene facts
|
| |
|---|---|
|
Headquarters (founded) |
Summit, N.J. (1980) |
|
Market Cap |
$41.8 billion |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$5.5 billion |
|
Management |
Chairman/CEO Robert Hugin CFO Jacqualyn Fouse |
|
Return on Equity (average, past 3 years) |
21.9% |
|
Cash / Debt |
$3.8 billion / $3.1 billion |
|
Competitors |
Johnson & Johnson (JNJ -0.69%) Pfizer (PFE -0.19%) Amgen (AMGN -0.19%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 1,594 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.
Earlier this month, one of those Fools, EpikurFool, succinctly summed up the Celgene bull case for our community:
High expected earnings growth, extremely profitable, still attractive valuation. Core holding in health care business.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
